Page last updated: 2024-11-11

nocloprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nocloprost: phalloidin transport inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917718
CHEMBL ID2106816
SCHEMBL ID436204
MeSH IDM0140429

Synonyms (20)

Synonym
zk-84726
nocloprost
zk 94 726
nocloprost [inn]
nocloprostum [latin]
(z)-7-((1r,2r,3r,5r)-5-chloro-3-hydroxy-2-((e)-(3r)-3-hydroxy-4,4-dimethyl-1-octenyl)cyclopentyl)-5-heptenoic acid
(z)-7-[(1r,2r,3r,5r)-5-chloro-3-hydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]cyclopentyl]hept-5-enoic acid
unii-7pom2oxt4q
7pom2oxt4q ,
79360-43-3
nocloprostum
CHEMBL2106816
prosta-5,13-dien-1-oicacid, 9-chloro-11,15-dihydroxy-16,16-dimethyl-, (5z,9b,11a,13e,15r)-
nocloprost [mart.]
SCHEMBL436204
Q27268691
CS-0024742
HY-106054
DTXSID101021624
AKOS040753302

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Thirty min after the first administration on the first day (single) and 30 min after the last administration in the morning of the 8th day (repeated premedication), pharmacokinetic examinations with retarded theophylline capsules (250 mg) or enteric coated tablets of diclofenac (50 mg) were performed."( Potential pharmacokinetic interactions of nocloprost clathrate with retarded theophylline and enteric coated diclofenac after single and repeated premedication in healthy volunteers.
Amon, I; Franke, G; Scheuch, E; Siegmund, W; Stolz, E; Zschiesche, M, 1993
)
0.55
" tmax showed a wide scatter, with an average value of about 30 min independent of the dose."( Pharmacokinetics of nocloprost in human volunteers and its relation to dose.
Brudny-Klöppel, M; Jakobs, U; Madetzki, C; Mahler, M; Tüber, U, 1993
)
0.61

Bioavailability

Nocloprost is a stable prostaglandin E2 analogue. It shows very high gastroprotective potency, relatively weak gastric inhibitory activity, and low systemic bioavailability after oral administration.

ExcerptReferenceRelevance
"Previous studies in animals and humans demonstrated that nocloprost, a stable prostaglandin E2 analogue, shows very high gastroprotective potency, relatively weak gastric inhibitory activity, and low systemic bioavailability after oral administration."( Effects of nocloprost on gastric functions in man.
Hebzda, Z; Konturek, SJ; Kwiecien, N; Maczka, J; Obtulowicz, W; Oleksy, J, 1991
)
0.92
" As far as diclofenac is concerned, single premedication increased significantly the rate of absorption and total body clearance but lowered the AUC of the NSAID."( Potential pharmacokinetic interactions of nocloprost clathrate with retarded theophylline and enteric coated diclofenac after single and repeated premedication in healthy volunteers.
Amon, I; Franke, G; Scheuch, E; Siegmund, W; Stolz, E; Zschiesche, M, 1993
)
0.55
"The pharmacokinetics and absolute bioavailability of nocloprost, a synthetic PGE2-analogue with cytoprotective properties, was investigated in human volunteers as a function of the dose."( Pharmacokinetics of nocloprost in human volunteers and its relation to dose.
Brudny-Klöppel, M; Jakobs, U; Madetzki, C; Mahler, M; Tüber, U, 1993
)
0.86
" The extent of bioavailability remained unchanged."( Effects of nocloprost (9 beta-chloro-16,16-dimethyl PG E2) on absorption and disposition of antipyrine and sulfamethazine in healthy volunteers.
Amon, I; Franke, G; Müller, C; Siegmund, W; Zschiesche, M, 1993
)
0.68

Dosage Studied

ExcerptRelevanceReference
" Our results identify the decreased expression of prostaglandin H synthase 1 and increased expression of leukotriene C(4) synthase as the key elements in AA metabolism that contribute to increased leukotriene C(4) and decreased anti-inflammatory prostaglandins after NSAID dosing in aspirin-intolerant patients."( Role of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study.
Brumen, M; Dobovišek, A; Fajmut, A, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (14.71)18.7374
1990's27 (79.41)18.2507
2000's0 (0.00)29.6817
2010's2 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.13 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]